Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.J&J says ADHD drug has less abuse-related effects
The data, from two sources – a national review of emergency department visits and a pharmacokinetic/pharmacodynamic study – highlights a possible benefit related to reduced abuse potential that
The data, from two sources – a national review of emergency department visits and a pharmacokinetic/pharmacodynamic study – highlights a possible benefit related to reduced abuse potential that
VKC is a rare and severe form of chronic allergic conjunctivitis affecting mostly children and young adults. It is characterized by painful ocular discomfort, itching and intense photophobia,
Under the terms of the license agreement with UBC, signed in September 1999, Chemokine was required to make milestone payments for certain technologies related to the company’s cancer
As part of the NDA submission, BioMarin has requested priority review status. Merck Serono expects to file a marketing authorization application for Kuvan with the European Medicines Agency
Safety and interim antibody data from the current phase III study highlighted the definitive and significant dose response observed between the 100mg, 300mg and 900mg doses of Riquent
The study is designed to assess the safety and potential efficacy of different doses of the drug, tgAAC94, administered directly to affected joints of patients with inflammatory arthritis.
The study is being conducted by Nordic Bioscience both in the European Union and in the US, and is planned to include more than 2000 patients. Calcitonin is
The company commented that the 500 liter-capacity fermentation process is sufficient for the initial commercialization of nimotuzumab, a humanized monoclonal antibody for the treatment of cancer. YM BioSciences,
Exelixis said that in preclinical studies the compound, XL019, had shown to be a potent, selective and orally available small molecule inhibitor of the cytoplasmic tyrosine kinase JAK2.
Clinical results demonstrate that the investigational candidate, Traficet-EN, was well tolerated and showed activity in the treatment of patients with active Crohn’s disease, the company said. Patients enrolled